Drug Trial Radar · NCT07024732
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jun 23, 2025
Primary completion
Apr 7, 2026
Study completion Apr 7, 2026
Sponsor
- Lead sponsor
- EyevensysIndustry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration
Conditions
- Dry Age Related Macular Degeneration
Interventions
PST-611Biological
PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Screening to week 16
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Cochin
Paris, France
CHU de Grenoble-Hôpital Michallon
Grenoble, France, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.